Kyrexa’s novel cancer therapy offers hope for durable veterinary and human treatments

Scotland-based Kyrexa claims rimcazole, traditionally seen as an unwanted side effect, can shrink tumours in dogs by targeting stress-adaptation pathways, with potential implications for human cancer treatments amid promising pilot results and plans for regulatory approval.

Kyrexa says a once-abandoned compound may now offer a safer route into veterinary oncology, after dog studies suggested rimcazole can shrink tumours without stripping away quality of life. The commercial stakes are wider than one animal medicine: the same biology could shape future human cancer development if the mechanism holds up outside the laboratory.

The company’s pitch rests on a revised view of rimcazole’s action on the dopamine transporter, long treated as an unwanted effect. Work described in Cancer Research in 2004 linked rimcazole to apoptosis in cancer cells, while later studies on the sigma-1 receptor and dopamine transporter helped support the idea that the two proteins interact in ways that alter tumour behaviour under stress.

Kyrexa argues that real cancers, unlike laboratory models, depend more heavily on this stress-adaptation pathway, which may explain why lower doses proved active in dogs with advanced disease. In pilot studies, the company reports tumour stabilisation and shrinkage, alongside what owners described as a striking return of vitality.

That matters because persistent, stem-like cancer cells are often blamed for relapse. If rimcazole can reach those cells as well as the bulk tumour, it could offer a more durable response than conventional chemotherapy alone. Kyrexa, founded in Scotland in 2023, is now seeking a regulator-backed path to licenced use in dogs.